Top-line results show that the two Phase 3 studies, BE HEARD I and BE HEARD II, met their primary and key secondary endpoints with statistical significance and.
/PRNewswire/ UCB, a global biopharmaceutical company, today announced that it will present 15 abstracts across its rheumatology portfolio at ACR Convergence.
/PRNewswire/ UCB, a global biopharmaceutical company, today announced that it will present 15 abstracts across its rheumatology portfolio at ACR Convergence.
New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress ycharts.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ycharts.com Daily Mail and Mail on Sunday newspapers.